https://www.selleckchem.com/pr....oducts/pf-06463922.h
Despite available meta-analyses, comparative efficacy and safety between bevacizumab and cetuximab-containing therapies in treating advanced colorectal cancer (CRC) still need to be elucidated. This meta-analysis aimed to investigate the efficacy and grade 3-5 treatment-related adverse events (TARE3-5) of bevacizumab versus cetuximab in treating advanced CRC. A random sample of 400 patients aged 65years or older from a clinical trial in four Swedish hospitals was selected. All patients' emergency department visits within 12months af
Like
Comment
Share
